We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively. Afterward, adjuvant TMZ chemotherapy was discontinued in one patient and the dosage of TMZ was reduced in the other. In addition to clinical status and magnetic resonance imaging, the biologic activity of the tumors was monitored by repeated methyl-11 C-l-methionine (MET) and 3′-deoxy-3′-18 F-fl uorothymidine (FLT) positron emission tomography (PET) studies in these patients. In these patients, repeated METand FLT-PET imaging documented complete response to the initial treatment regimen, including resection, radiation, and TMZ, and during the course of the disease, recurrent, uncontrollable tumor activity. Continuation or dose escalation of TMZ in both patients was shown to be ineffective to overcome the metabolic activity of the tumor. Our data suggest that repeated MET-and FLT-PET imaging provide information on the biologic activity of a tumor that is highly useful to monitor and detect changes in activity. in patients with glioblastoma multiforme (GBM), it was shown that survival was longer for patients who had been assigned combination treatment. 4 At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus TMZ and 12.1 months with radiotherapy alone. The 2-year survival rate was 26.5% with radiotherapy plus TMZ and 10.4% with radiotherapy alone.
in patients with glioblastoma multiforme (GBM), it was shown that survival was longer for patients who had been assigned combination treatment. 4 At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus TMZ and 12.1 months with radiotherapy alone. The 2-year survival rate was 26.5% with radiotherapy plus TMZ and 10.4% with radiotherapy alone.
Based on these results, current therapy recommendations for patients with GBM are maximal surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with TMZ for 6 to 12 months. 4 -6 Owing to the poor prognosis for patients with GBM, there are no clear further therapy recommendations for the period after 12 months of adjuvant TMZ chemotherapy. Moreover, if patients respond to adjuvant TMZ, it is unclear how long TMZ should be administered. Imaging of the metabolic activity of tumor tissue in patients with GBM by positron emission tomography (PET) might allow for separation of therapy responders from nonresponders and prove useful for individual therapy decisions.
We present two patients with GBM with unusually stable clinical course and long-term survival who were treated with adjuvant TMZ for more than 12 months. In addition to clinical status and magnetic resonance imaging (MRI), the biologic activity of the tumors was monitored by repeated methyl- 11 C-l-methionine (MET) and 3′-deoxy-3′- 18 F-fl uorothymidine (FLT) PET studies in these rare individual GBM patients. Additionally, we performed T EMOZOLOMIDE (TMZ) is an oral, secondgeneration alkylating agent that was licensed in 1999 for the treatment of patients with malignant glioma showing recurrence or progression after standard therapy. For patients with recurrent malignant glioma, TMZ provides a therapeutic option with a predictable safety profi le, clinical effi cacy, and convenient dosing, which leads to important quality of life benefi ts. 1 TMZ is now standard adjuvant therapy in patients with newly diagnosed malignant glioma 2 in combination with radiotherapy. 3 -5 Owing to systemic adverse effects and possible neurotoxicity, adjuvant chemotherapy for patients with gliomas has not gained universal acceptance yet. 2 However, in a recent randomized controlled trial of radiotherapy alone versus radiotherapy with concomitant and adjuvant TMZ a noninvasive quantifi cation of the FLT-PET data using kinetic modeling for assessment of the proliferative activity of the GBM in one patient.
Methods

PET Studies
MET-and FLT-PET images were acquired on a Siemens ECAT EXACT or ECAT EXACT HR (CTI/Siemens, Knoxville, TN). Ten-minute transmission scans with three rotating 68 Ga/ 68 Ge sources were obtained before tracer application to allow for attenuation correction. After injection of 20 mCi (740 MBq) MET, synthesized according to the method of Berger and colleagues, 7 tracer accumulation was recorded in three-dimensional mode over 60 minutes in 47 transaxial slices from the entire brain. Summed activity from 20 to 60 minutes after tracer injection was used for image reconstruction. FLT was synthesized according to the modifi ed method of Machulla and colleagues 8 , 9 and 10 mCi (370 MBq) was injected. FLT-PET images were acquired as a 90-minute dynamic set (6 × 10, 3 × 20, 2 × 30, 2 × 60, 2 × 150, 16 × 300 seconds) as described previously. 10 Images were reconstructed with Fourier rebinning and fi ltered backprojection with a ramp fi lter. Images were corrected for scatter, attenuation, and random coincidences. Spatial resolution was 6 mm or better in all dimensions.
For data assessment, uptake ratios in MET-and FLT-PET images were determined as previously described. 10 , 11 In brief, a circular region of interest (ROI) of 8 mm in diameter was placed over the tumor area and normalized to a reference ROI placed over intact brain tissue in the corresponding contralateral region or, if impossible because of the tumor location, on intact brain regions.
As described previously, kinetic modeling of FLT-PET data using image-derived input functions was performed 12 and kinetic rate constants K 1 (transport across the bloodbrain barrier) and K i (metabolic rate constant or net infl ux constant) were calculated. Values of K 1 and K i were presented in mL/cm 3 /min ± standard deviation.
Results
Case Presentations
Patient 1
A Six months after discontinuation of TMZ, a follow-up MET-PET showed recurrence of metabolically active tumor mass lateral to the resection defect without clinical symptoms (see Figure 2 ). The MET uptake was increased 1.8-fold in comparison to the unaffected contralateral brain tissue. Arrow indicates a mitotic fi gure (MIB-1 immunohistochemistry, slight counterstaining with hemalum; ×400 original magnifi cation).
A B
follow-up MET-PET was performed 3 months later and showed similar uptake but an increased size of the MET uptake pattern (see Figure 2 ). The corresponding MRI was consistent with a recurrence of GBM and showed a positive contrast enhancement (see Figure 2 ). The patient was still free from clinical symptoms, but 1 month later, the fi rst epileptic seizure occurred. During the course of the disease, the frequency of epileptic seizures increased up to daily seizures. Owing to clinical deterioration and imaging-based tumor progression, TMZ chemotherapy was discontinued. The patient died 8 months after the last MET-PET in October 2004.
Patient 2
A 53-year-old patient developed headache, weight loss, dizziness, and night sweats 2 months prior to admission in June 2001. Neurologic examination on admission showed no relevant defi cit. MRI revealed a contrast-enhancing, tumor-suspicious, polycystic lesion in the right temporal lobe ( Figure 3 FLT-and MET-PET imaging 7 months after dose reduction of TMZ showed a new, small, metabolically active tumor mass at the right anterior part of the corpus callosum without contact to the primary tumor localization (see Figure 5 ). The MET uptake ratio was 1.9-fold increased in comparison to the unaffected contralateral brain tissue, and the FLT uptake ratio was 2.6-fold increased. Kinetic modeling of the FLT data revealed a K 1 value of 0.004874 mL/cm 3 /min ± 0.0029 and a K i value of 0.001517 mL/cm 3 /min ± 0.0021, respectively. TMZ chemotherapy was escalated according to a 1-week on/1-week off regimen. 13 The follow-up PET imaging 3 months after therapy escalation showed a MET uptake pattern at the right anterior part of the corpus callosum with a massive increase in size and uptake ratio to 3.4-fold (see Figure 5 ). In comparison with MET-PET, the FLT-PET showed as well a similar same-sized lesion but a higher FLT-uptake ratio (7.5-fold; see Figure 5 ). Kinetic modeling of this FLT-PET scan revealed a dramatic 18-fold increased value of K i (0.027383 mL/cm 3 /min ± 0.0101) and a 25-fold increased K 1 value (0.119845 mL/cm 3 /min ± 0.0089). The corresponding MRI was consistent with a recurrence of 1st MET PET after 6 months GBM and showed a positive contrast enhancement (see Figure 5 ). After maximal resection of the recurrent GBM ( Figure 4, D-F ) , the patient died 6 months later after having received palliative care.
Discussion
We present two patients with GBM with a stable clinical course while on long-term adjuvant TMZ chemotherapy who both relapsed after discontinuation or reduction of TMZ. In these patients, repeated MET-PET imaging combined with two additional serial FLT-PET scans including kinetic modeling in one patient documented a complete response to the initial treatment regimen, including resection, radiation, and TMZ, and during the course of the disease, recurrent, uncontrollable tumor activity. Treatment decisions (decision against discontinuation of adjuvant TMZ chemotherapy when PET fi ndings show no increased metabolic activity as well as the continuation or dose escalation of TMZ in both patients at the time of recurrence) were signifi cantly supported by the fi ndings of the metabolic PET images.
Once the tumors had relapsed, continuation or dose escalation of TMZ in both patients was shown to be ineffective in overcoming the metabolic activity of the tumor. A possible hypothesis for TMZ ineffectiveness might be an accelerated mutagenic process in resistant clones as a consequence of continued exposure to alkylating agents. Recent evidence suggests that the mismatch repair gene MSH6 in gliomas is inactivated owing to mutations. In consequence, alkylating agents convert from their function to induce tumor cell death to the promotion of neoplastic progression. 14 In clinical routine, long-term adjuvant TMZ chemotherapy in patients with malignant gliomas with respect to possible short-and long-term complications is being monitored clinically and by MRI studies. Metabolic tracers, such as positron emitter-labeled amino acids, have been proposed as new indicators of tumor activity. 15 A previous study revealed that monitoring of metabolic changes with MET-PET may provide an objective measure for response to TMZ treatment; thus, it should be integrated as an improved imaging modality to monitor biologic tumor activity. A , An anaplastic cellular glioma composed of small astrocytic tumor cells, geographic necrosis, and large, thrombosed tumor vessels ( asterisks ) (hematoxylin-eosin stain; ×200 original magnifi cation). B , Note the prominent microvascular proliferation with multilayered "glomeruloid tuft" glioma vessels (hematoxylin-eosin stain; ×400 original magnifi cation). C , Proliferative activity is prominent (MIB-1 immunohistochemistry, slight counterstaining with hemalum; ×400 original magnifi cation). D , The recurrency is composed predominantly of small astrocytic tumor cells with a prominent network of pathologic vessels (hematoxylin-eosin stain; ×200 original magnifi cation). E , Marked nuclear atypia with multinucleated tumor cells ( arrows ) (hematoxylin-eosin stain; ×400 original magnifi cation). F , Brisk proliferative activity (MIB-1 immunohistochemistry, slight counterstaining with hemalum; ×400 original magnifi cation). MET-PET may be a valuable method to differentiate therapy responders from nonresponders and may provide important information for making treatment decisions, especially in nonresponders. MET-PET has been used to study the effects of radiotherapy in gliomas. 17 -20 It provides a more accurate assessment of tumor extent than contrast enhancement on computed tomography and MRI. 21 -24 Accumulation is largely due to carrier-mediated transport, which is not altered by dexamethasone 21 and also permits the alternative method of perfusion MRI distinction between tumors and contrastenhancing necrosis. 25 -27 MET undergoes complex metabolism and is incorporated into proteins; therefore, increased uptake may refl ect the metabolic needs of brain tumors. 28 The effect of chemotherapy with procarbazine, lomustine, and vincristine in an anaplastic oligoastrocytoma was monitored by repeated MET-PET 29 successfully and highlighted the potential of this technique to monitor chemotherapy. Most importantly, MET-PET may allow the prediction of clinical outcome in patients with gliomas within 3 months after onset of chemotherapy, 16 which makes it a valuable addition to conventional MRI.
In comparison with the imaging modalities MET-PET and gadolinium-enhanced MRI, FLT-PET was recently characterized in a heterogeneous glioma patient collective and seems to yield additional information on the activity and extent of gliomas. 10 Furthermore, FLT-PET can be used to evaluate the proliferative activity of primary brain tumors and to detect recurrent gliomas, especially malignant brain tumors. 30 -33 Relative FLT uptake within gliomas is greater than relative MET uptake, 10 indicating the possible role of FLT as a more specifi c tumor marker than [ 18 F]-labeled fl uorodeoxyglucose 32 , 34 and MET, 35 , 36 especially when kinetic modeling is used for assessment of tumor proliferation as a marker for the real biologic activity in patients with newly diagnosed high-grade glioma. 37 In the second patient presented here, the recurrent tumor tissue was detected by both FLT-PET including kinetic modeling and MET-PET.
Our data suggest that repeated MET-and FLT-PET imaging including kinetic modeling provide information on the biologic activity of a tumor that is highly useful to monitor and detect changes in activity. The observation that the metabolic changes occurred after discontinuation and dose reduction of adjuvant TMZ chemotherapy needs further exploration of whether TMZ should be given in patients with GBMs even when they do not show any active tumor. 
